Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
ADXS's Cash-to-Debt is ranked higher than
87% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. ADXS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ADXS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 4.63 Max: No Debt
Current: No Debt
0
No Debt
Equity-to-Asset 0.55
ADXS's Equity-to-Asset is ranked lower than
62% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ADXS: 0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
ADXS' s Equity-to-Asset Range Over the Past 10 Years
Min: -10.71  Med: 0.54 Max: 0.93
Current: 0.55
-10.71
0.93
Interest Coverage No Debt
ADXS's Interest Coverage is ranked higher than
83% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ADXS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ADXS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -9.99
Beneish M-Score: -3.84
WACC vs ROIC
28.57%
522.31%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -1137.94
ADXS's Operating Margin % is ranked lower than
77% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. ADXS: -1137.94 )
Ranked among companies with meaningful Operating Margin % only.
ADXS' s Operating Margin % Range Over the Past 10 Years
Min: -16623.33  Med: -1934.3 Max: -818.95
Current: -1137.94
-16623.33
-818.95
Net Margin % -1062.82
ADXS's Net Margin % is ranked lower than
77% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. ADXS: -1062.82 )
Ranked among companies with meaningful Net Margin % only.
ADXS' s Net Margin % Range Over the Past 10 Years
Min: -8206.06  Med: -1746.85 Max: 3096.67
Current: -1062.82
-8206.06
3096.67
ROE % -144.27
ADXS's ROE % is ranked lower than
84% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. ADXS: -144.27 )
Ranked among companies with meaningful ROE % only.
ADXS' s ROE % Range Over the Past 10 Years
Min: -341.26  Med: -96.61 Max: -62.63
Current: -144.27
-341.26
-62.63
ROA % -84.33
ADXS's ROA % is ranked lower than
82% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. ADXS: -84.33 )
Ranked among companies with meaningful ROA % only.
ADXS' s ROA % Range Over the Past 10 Years
Min: -386.9  Med: -108.51 Max: 45.93
Current: -84.33
-386.9
45.93
ROC (Joel Greenblatt) % -1012.52
ADXS's ROC (Joel Greenblatt) % is ranked lower than
62% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. ADXS: -1012.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ADXS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -27114.29  Med: -13056.94 Max: 1183.45
Current: -1012.52
-27114.29
1183.45
3-Year Revenue Growth Rate 72.40
ADXS's 3-Year Revenue Growth Rate is ranked higher than
92% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ADXS: 72.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ADXS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: 72.4
Current: 72.4
0
72.4
3-Year EBITDA Growth Rate -28.60
ADXS's 3-Year EBITDA Growth Rate is ranked lower than
79% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. ADXS: -28.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ADXS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 13 Max: 30.2
Current: -28.6
0
30.2
3-Year EPS without NRI Growth Rate -33.50
ADXS's 3-Year EPS without NRI Growth Rate is ranked lower than
85% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. ADXS: -33.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ADXS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 42.1
Current: -33.5
0
42.1
GuruFocus has detected 1 Warning Sign with Advaxis Inc ADXS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ADXS's 30-Y Financials

Financials (Next Earnings Date: 2018-10-31 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

ADXS Guru Trades in Q3 2017

Paul Tudor Jones 16,580 sh (New)
» More
Q4 2017

ADXS Guru Trades in Q4 2017

Jim Simons 492,394 sh (New)
Paul Tudor Jones Sold Out
» More
Q1 2018

ADXS Guru Trades in Q1 2018

Jim Simons 992,394 sh (+101.54%)
» More
Q2 2018

ADXS Guru Trades in Q2 2018

Jim Simons 436,494 sh (-56.02%)
» More
» Details

Insider Trades

Latest Guru Trades with ADXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Advaxis Inc does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2834
Compare:XKRX:038070, NAS:CDTX, NAS:GNMX, ASX:TLX, OTCPK:GBLX, TSE:2191, XPAR:ABVX, AMEX:RFL, XPAR:SIGHT, XKRX:000220, ASX:CYP, TSE:4588, XBRU:BOTHE, NAS:CRIS, NAS:FLKS, ROCO:6469, XKRX:203400, NAS:BLRX, XKRX:138610, XKRX:106190 » details
Traded in other countries:FAD1.Germany,
Headquarter Location:USA
Advaxis Inc focuses on discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies.

Advaxis Inc is a clinical stage biotechnology company operating in the United States. It focuses on discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology which utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate Specific Antigen (PSA) associated with prostate cancer.

Top Ranked Articles about Advaxis Inc

Recent Analysis Shows Liberty TripAdvisor, Control4, Ferro, Advaxis, Frontier Communications, and Newpark Resources Market Influences — Renewed Outlook, Key Drivers of Growth
New Research Coverage Highlights Knowles, Advaxis, G-III Apparel Group, LTD, National CineMedia, Haemonetics, and MACOM Technology Solutions — Consolidated Revenues, Company Growth, and Expectations for 2018
Analysis: Positioning to Benefit within Advaxis, e.l.f. Beauty, Heron Therapeutics, PVH, Energy Recovery, and A. O. Smith — Research Highlights Growth, Revenue, and Consolidated Results
Research Report Identifies Diebold, Liberty TripAdvisor, Paycom Software, BJ's Restaurants, Advaxis, and Sanmina with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
3 Stocks Move on Thursday Hovnanian Enterprises, Bed Bath & Beyond, Advaxis impacted by quarterly results
Shares of Hovnanian Enterprises Inc. (NYSE:HOV) jumped more than 2% on the back of the company reporting its financial results for the fourth quarter of fiscal 2018, which ended Oct. 31. The company posted adjusted EPS of eight cents on revenue of $721.69 million, which represented a 10.4% decline from the prior-year quarter. The company beat EPS expectations by six cents, and revenue beat the consensus estimate by $113.02 million. Read more...
Aratana Therapeutics Granted Conditional License for a Canine Osteosarcoma Therapeutic
Analysis: Positioning to Benefit within Diebold, Liberty TripAdvisor, Paycom Software, First American, Advaxis, and Sanmina — Research Highlights Growth, Revenue, and Consolidated Results
Insiders Roundup: Twitter, McKesson Make Biggest Trades Largest insider trades of the Week
The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “Sept. 2017” and All Insider Sales to “$5,000,000+." Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.44
ADXS's PB Ratio is ranked higher than
81% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ADXS: 1.44 )
Ranked among companies with meaningful PB Ratio only.
ADXS' s PB Ratio Range Over the Past 10 Years
Min: 1.28  Med: 3.32 Max: 26.44
Current: 1.44
1.28
26.44
PS Ratio 6.05
ADXS's PS Ratio is ranked higher than
62% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ADXS: 6.05 )
Ranked among companies with meaningful PS Ratio only.
ADXS' s PS Ratio Range Over the Past 10 Years
Min: 5.44  Med: 75 Max: 2037.14
Current: 6.05
5.44
2037.14
EV-to-EBIT -0.31
ADXS's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. ADXS: -0.31 )
Ranked among companies with meaningful EV-to-EBIT only.
ADXS' s EV-to-EBIT Range Over the Past 10 Years
Min: -28.4  Med: -3.3 Max: 25.8
Current: -0.31
-28.4
25.8
EV-to-EBITDA -0.31
ADXS's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. ADXS: -0.31 )
Ranked among companies with meaningful EV-to-EBITDA only.
ADXS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -30.6  Med: -3.4 Max: 22.8
Current: -0.31
-30.6
22.8
EV-to-Revenue 3.43
ADXS's EV-to-Revenue is ranked higher than
88% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. ADXS: 3.43 )
Ranked among companies with meaningful EV-to-Revenue only.
ADXS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5  Med: 89.5 Max: 1645.9
Current: 3.43
0.5
1645.9
Current Ratio 3.95
ADXS's Current Ratio is ranked lower than
60% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ADXS: 3.95 )
Ranked among companies with meaningful Current Ratio only.
ADXS' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.42 Max: 29.36
Current: 3.95
0.01
29.36
Quick Ratio 3.95
ADXS's Quick Ratio is ranked lower than
57% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. ADXS: 3.95 )
Ranked among companies with meaningful Quick Ratio only.
ADXS' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.42 Max: 29.36
Current: 3.95
0.01
29.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -28.00
ADXS's 3-Year Average Share Buyback Ratio is ranked lower than
72% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. ADXS: -28.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ADXS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -119.8  Med: -44.9 Max: -28
Current: -28
-119.8
-28

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.09
ADXS's Price-to-Net-Cash is ranked higher than
77% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. ADXS: 4.09 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ADXS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.14  Med: 4.76 Max: 375
Current: 4.09
2.14
375
Price-to-Net-Current-Asset-Value 2.37
ADXS's Price-to-Net-Current-Asset-Value is ranked higher than
83% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. ADXS: 2.37 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ADXS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.11  Med: 3.81 Max: 93.75
Current: 2.37
2.11
93.75
Price-to-Tangible-Book 1.70
ADXS's Price-to-Tangible-Book is ranked higher than
83% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. ADXS: 1.70 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ADXS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.58  Med: 3.56 Max: 56.48
Current: 1.7
1.58
56.48
Price-to-Median-PS-Value 0.08
ADXS's Price-to-Median-PS-Value is ranked higher than
96% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. ADXS: 0.08 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ADXS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 0.72 Max: 15.74
Current: 0.08
0.08
15.74
Earnings Yield (Greenblatt) % -325.83
ADXS's Earnings Yield (Greenblatt) % is ranked lower than
99% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. ADXS: -325.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ADXS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2360.9  Med: -28.8 Max: 5
Current: -325.83
-2360.9
5

More Statistics

Revenue (TTM) (Mil) $6.70
EPS (TTM) $ -1.60
Beta4.25
Volatility54.79%
52-Week Range $0.78 - 4.97
Shares Outstanding (Mil)69.50

Analyst Estimate

Oct18 Oct19 Oct20 Oct21
Revenue (Mil $) 6 5 5 11
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -1.01 -0.59 -0.33 -0.29
EPS without NRI ($) -1.01 -0.59 -0.33 -0.29
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}